Table of Content

Introduction
Executive Summary
Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
• SYK Receptor - Overview
• Structure and Signaling of the SYK Receptor
• Regulation of Synthesis and Release of SYK
• SYK Metabolism
• SYK Receptor Antagonists
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Spleen Tyrosine Kinase (SYK) Inhibitors
In-depth Commercial Assessment
• Spleen Tyrosine Kinase (SYK) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
• Comparative Analysis
TOP 1630: TopiVert
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
Cevidoplenib: Genosco
• Product Description
• Research and Development
• Product Development Activities
PRT 2761: Portola Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Early Stage Products (Phase I/II)
• Comparative Analysis
Gusacitinib: Asana BioSciences
• Product Description
• Research and Development
• Product Development Activities
Early Stage Products (Phase I)
• Comparative Analysis
Mivavotinib: Takeda Oncology
• Product Description
• Research and Development
• Product Development Activities
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Research programme: small molecule therapeutics: Genosco
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
Comparative Analysis
• Spleen Tyrosine Kinase (SYK) Inhibitors Key Companies
• Spleen Tyrosine Kinase (SYK) Inhibitors Key Products
• Spleen Tyrosine Kinase (SYK) Inhibitors- Unmet Needs
Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
• Spleen Tyrosine Kinase (SYK) Inhibitors- Future Perspectives and Conclusion
• Spleen Tyrosine Kinase (SYK) Inhibitors Analyst Views
• Spleen Tyrosine Kinase (SYK) Inhibitors Key Companies
Appendix



List of Figures


Figure 1 Total Products for Spleen Tyrosine Kinase (SYK) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

 

List of Tables


Table 1 Total Products for Spleen Tyrosine Kinase (SYK) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products